Literature DB >> 16355556

Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.

Debra Wolff, Eva Culakova, Marek S Poniewierski, Gary H Lyman, David C Dale, Jeffrey Crawford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16355556

Source DB:  PubMed          Journal:  J Support Oncol        ISSN： 1544-6794


× No keyword cloud information.
  3 in total

1.  Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.

Authors:  Rachel Wuerstlein; Nadia Harbeck; Eva-Maria Grischke; Dirk Forstmeyer; Raquel von Schumann; Petra Krabisch; Kerstin Lüdtke-Heckenkamp; Andrea Stefek; Oliver Stoetzer; Andrea Grafe; Gabriele Kaltenecker; Helmut Forstbauer; Doris Augustin; Iris Schrader; Joke Tio; Ulrike Nitz; Oleg Gluz; Ronald E Kates; Monika Karla Graeser
Journal:  Breast Care (Basel)       Date:  2020-04-06       Impact factor: 2.860

2.  Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.

Authors:  Stefan Fruehauf; Burkhard Otremba; Oliver Stötzer; Christine Rudolph
Journal:  Adv Ther       Date:  2016-10-14       Impact factor: 3.845

3.  Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.

Authors:  Sophie Nahon; Mansour Rastkhah; Meher Ben Abdelghani; Ravaka-Fatoma Soumoudronga; Isabelle Gasnereau; Jean-Luc Labourey
Journal:  Support Care Cancer       Date:  2015-10-27       Impact factor: 3.359
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.